06833 SINCO PHARMA
- 0.237
- -0.001-0.42%
SINCO PHARMA News
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
興科蓉醫藥：年報 2023
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Xingkerong Pharmaceutical (6833.HK): Revenue increased 11.8% year over year, ready to go
In 2023, in an environment where external uncertainties still exist, the Hong Kong stock pharmaceutical market experienced significant fluctuations, and the sector is still below the historical valuation center. However, there are still excellent companies in the pharmaceutical sector that have shown good ability to cross the cycle, and have performed well with high performance flexibility and stable fundamentals, such as Xingkerong Pharmaceutical, a leading marketing, promotion and channel management service provider in the domestic pharmaceutical industry. Recently, Xingkerong Pharmaceutical announced its 2023 annual results. According to the results announcement, the company's revenue achieved a steady increase of 11.8%, reaching RMB 2.54 billion. This one percent
SINCO PHARMA To Go Ex-Dividend On May 20th, 2024 With 0.0039 HKD Dividend Per Share
March 27th - $SINCO PHARMA(06833.HK)$ is trading ex-dividend on May 20th, 2024. Shareholders of record on May 21st, 2024 will receive 0.0039 HKD dividend per share on June 4th, 2024. The ex-divide
Sinco Pharmaceuticals' 2023 Profit Declines on Higher Tax Payments
Sinco Pharmaceuticals Holdings' (HKG:6833) attributable profit declined to 42.4 million yuan, or 0.021 yuan per share, in 2023, from 69.5 million yuan, or 0.034 yuan per share, in 2022, according to a
Xingkerong Pharmaceutical (06833) Announces 2023 Annual Results, Excellent Core Product Results, Dual Track Layout Continues to Deepen and Advance
The Zhitong Finance App learned that on the evening of March 26, Xingkerong Pharmaceutical (06833) announced its 2023 annual results, with revenue growth of 11.8% to RMB 2,540.1 million. Among them, sales revenue of human albumin injections increased by about RMB 249.8 million, and revenue from the medical and aesthetic business increased by RMB 13.7 million. During the reporting period, the company's gross profit increased by RMB 17.4 million to RMB 323.3 million. The increase in gross profit was mainly due to increased revenue from human albumin sales and medical and aesthetic services. At the same time, in order to return long-term shareholders' support, the company's board of directors recommended declaring a final dividend per share
Xingkerong Pharmaceutical (06833.HK) revenue increased 11.8% to 2.54 billion yuan in 2023
Gelonghui, March 26, 丨 Xingkerong Pharmaceutical (06833.HK) announced that in its annual results for the year ended December 31, 2023, the Group's revenue increased 11.8% to RMB 2.54 billion. Among them, sales revenue of human albumin injections increased by about RMB 250 million, mainly due to the increase in sales volume. During the reporting period, net profit attributable to company owners was RMB 42.4 million; basic and apportioned profit per share was RMB 0.02 (2022: basic and diluted earnings per share of RMB 0.03). Board resolution for the year ended 31 December 2023
Xingkerong Pharmaceutical (06833) announced annual results. Profit attributable to shareholders of RMB 42.352 million decreased by 39.03% year-on-year, with final interest of HK0.39 cents per share
Xingkerong Pharmaceutical (06833) announced the results for the year ended December 31, 2023. The group's beneficiaries...
Xingkerong Pharmaceutical (06833) will pay a final dividend of HK$0.0039 per share on June 4
Xingkerong Pharmaceutical (06833) announced that the company will distribute the end of 2023 on June 4, 2024...
SINCO PHARMA: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Xing Kerong Pharmaceutical (06833): Huang Zhijian was appointed as Executive Director
Xingkerong Pharmaceutical (06833) announced that Li Jianwei has resigned as the company's joint company secretary and the Hong Kong Stock Exchange Limited...
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
Xingkerong Pharmaceutical (06833.HK) held a board meeting on March 26 to consider and approve annual results
Gelonghui, March 14, 丨 Xingkerong Pharmaceutical (06833.HK) announced that the company will hold a board meeting on March 26, 2024 (Tuesday) to consider and approve the results and publication of the company and its subsidiaries for the year ended 31 December 2023, and to consider recommending payment of a final dividend (if any).
SINCO PHARMA: DATE OF BOARD MEETING
Analysis
Price Target
No Data
